Raman Singh

Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.

Juniper Biologics Pte Ltd is a science-led pharmaceutical company based in Singapore, Singapore. Juniper Biologics is backed by the Sylvan Group and is focused on delivering novel therapies to improve the health and quality of life of patients. The Singaporean company has a growing presence in oncology and oncology supportive care, rare/orphan diseases, and gene therapy. The company was founded with a vision to provide treatments for unmet medical needs in specialist therapy areas. Raman Singh has been the CEO of the company since 2020.

Mundipharma Pte Ltd. develops pharmaceutical products. Its therapy area includes analgesia, oncology, ophthalmology, respiratory, specialty care, and consumer healthcare. The company was founded in 2004 and is headquartered in Singapore.

Abbott Korea Ltd. engages in the distribution of medical equipment, reagents, medicines, nutritional products, infant formula and baby foods. The company was founded on May 24, 1988 and is headquartered in Seoul, South Korea.